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Abstract
Objective To determine whether nutritional supplementation during
pregnancy is associated with a reduced risk of autism spectrum disorder
(ASD) with and without intellectual disability in offspring.
Design Observational prospective cohort study using multivariable
logistic regression, sibling controls, and propensity score matching.
Setting Stockholm County, Sweden.
Participants 273 107 mother-child pairs identified through population
registers. The study sample was restricted to children who were aged
4 to 15 years by the end of follow-up on 31 December 2011 and were
born between 1996 and 2007.
Exposures Multivitamin, iron, and folic acid supplement use was reported
at the first antenatal visit.
Main outcome measure Diagnosis of ASD with and without intellectual
disability in children determined from register data up to 31 December
2011.
Results Prevalence of ASD with intellectual disability was 0.26% (158
cases in 61 934) in the maternal multivitamin use group and 0.48% (430
cases in 90 480) in the no nutritional supplementation use group.
Maternal multivitamin use with or without additional iron or folic acid, or
both was associated with lower odds of ASD with intellectual disability
in the child compared with mothers who did not use multivitamins, iron,
and folic acid (odds ratio 0.69, 95% confidence interval 0.57 to 0.84).
Similar estimates were found in propensity score matched (0.68, 0.54
to 0.86) and sibling control (0.77, 0.52 to 1.15) matched analyses, though
the confidence interval for the latter association included 1.0 and was
therefore not statistically significant. There was no consistent evidence
that either iron or folic acid use were inversely associated with ASD
prevalence.
Conclusions Maternal multivitamin supplementation during pregnancy
may be inversely associated with ASD with intellectual disability in
offspring. Further scrutiny of maternal nutrition and its role in the cause
of autism is recommended.
Introduction
With the heritability of autism spectrum disorders (ASD)
estimated to be between 50% and 80%,1 2 non-heritable risk
factors contribute to a substantial proportion of ASD risk.
Research suggests that ASD develops antenatally.3-5 Maternal
nutrition influences neurodevelopment6-8 and could influence
the risk of ASD.9 However, results from population based studies
have been inconsistent. An American case-control study
(CHildhood Autism Risks from Genetics and Environment
(CHARGE))10 and a Norwegian cohort study (Norwegian Mother
and Child Cohort Study (MoBa))11 reported reduced risks of
ASD with maternal folic acid supplementation and intake in the
periconceptional period and during early pregnancy. Conversely,
a study of the Danish National Birth Cohort (DNBC) reported
no associations between early folic acid or multivitamin
supplementation and risk of ASD.12 Maternal iron intake13 and
antenatal vitamin use14 were both associated with a reduced risk
of ASD in CHARGE, whereas no association between ordinary
multivitamin use and ASD was reported.14 Clarifying the
potential role of nutritional supplements is difficult, given the
potential for the cause of ASD to differ by the presence of
intellectual disability,15-17 although this has not been well studied
in the context of nutritional supplementation.
This association might be confounded by maternal
characteristics9 18—namely, mothers who have a given dietary
pattern are likely to be different from those who do not have
that dietary pattern; potential differences may include
socioeconomic characteristics, disease status, healthy
behaviours, or pregnancy characteristics.9 18 If these differences
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are not properly accounted for, then results may be owing to
confounding.
In the present study, we used three analytic strategies to
elucidate potential associations between maternal nutritional
supplementation with multivitamins, iron, and folic acid and
risk of ASD in offspring with and without intellectual disability.
These included sibling controls to account for familial,
environmental, and genetic confounding; propensity score
matching to ensure balanced comparisons between exposed and
unexposed children; and multivariable regression with
adjustment for a large number of covariates. The sibling matched
analyses serve as a guide as to whether estimates are confounded
by unobserved shared familial confounders but have low
statistical power. The propensity score matched analyses are
intended to help determine whether confounding from observed
characteristics unduly influences results but are not necessarily
generalizable. The multivariable regression analysis in the whole
sample provides the most generalizable and interpretable
estimates but is the most susceptible to limitations such as
confounding from observed and unobserved characteristics. The
study was designed to use the different strengths of the three
analytic approaches to gauge robustness of findings.
Methods
Study sample
Data were drawn from the Stockholm youth cohort, a population
register based cohort of children living in Stockholm County,
Sweden, for at least four years between 2001 and 2011.19 The
study sample was, for the purpose of availability of data on
supplement use, restricted to children who were born in Sweden
between 1996 and 2007 (ie, aged 4 to 15 years at the end of
follow-up on 31 December 2011). We excluded children who
were not in the medical birth register (n=17 029), not linked to
birth mother (n=41), adopted (n=193), or had missing data on
family disposable income (n=298) or maternal age (n=5) (fig
1⇓). Children are recorded in the medical birth register if birth
records are sent from the delivery hospital to the register.20 An
earlier report about the quality of the medical birth register20
cited that up to 2% of children born in Sweden are not recorded
in the register; however, the report acknowledged that this rate
has recently increased.
Sibling analyses were based on a subset of cohort, with
singletons removed; propensity score analyses were based on
a subset of matched groups; and multivariable regression
analyses were based on the whole cohort (fig 1⇓). Siblings were
restricted to members of the study sample born within the study
period and were defined as having the same birth mother.
Case ascertainment
Data on autism spectrum disorder (ASD) were drawn from
computerized registers covering all pathways of ASD diagnosis
and care in Stockholm County. Case ascertainment is described
in detail elsewhere.19 Paediatric healthcare and habilitation (ie,
disability support) services are available free of charge in
Sweden.
Developmental screening occurs at regular intervals, whereby
children with suspected autism are referred for structured
diagnostic assessments by specialists.21 ASD is recorded using
ICD-10 (international classification of diseases, 10th revision)
code F84 and DSM-IV (Diagnostic and Statistical Manual of
Mental Disorders, fourth edition, text revision) code 299 in
registers covering child and adolescent mental health,
habilitation, and paediatric inpatient and outpatient services. In
this study, outcomes of interest were any ASD and ASD with
or without a recorded intellectual disability in registers using
ICD-10 codes F70-79 and DSM-IV codes 317-31916 and
supplemented with data from the habilitation register, which
categorizes autism by comorbid intellectual disability.19 For any
ASD, a review of medical records indicated that 96.0% of
recorded cases were consistent with diagnostic criteria. When
assessing the validity of ASD case status by co-occurring
intellectual disability, ASD with intellectual disability was
confirmed in 68 of 90 cases (76%); 17 of the 22 cases of
non-confirmed ASD with intellectual disability (77%) had ASD
but no documentation of intellectual disability.19
Maternal supplement use
Web appendix 1 provides recommendations about supplement
use for pregnant women during the study period. Briefly,
pregnant women are advised to take 400 μg/day of folic acid
during the first trimester.22 Through 2008, 100 mg/day of iron
was recommended for pregnant women during weeks 20 to 24
but is now only recommended (200 mg/day) for pregnant women
who are anemic.23 No guidelines were available for multivitamin
use during the study period. Self reported supplement and drug
use was assessed at the first antenatal visit. Gestational week at
the first antenatal visit was recorded in the medical birth register
from mid-1995 onwards (median 10.7 weeks, interquartile range
9.0-12.7 weeks).20 Most women attended scheduled antenatal
care visits; these consultations are free of charge in Sweden.24
Using a standardized form, a midwife interviewed the woman
at the first visit and asked about any drug use during pregnancy.
Drug information was recorded by the midwife and later
transcribed into the medical birth register as Anatomical
Therapeutic Chemical (ATC) classification codes (see web
appendix eTable 2) or free text.
We individually created variables based on ATC code and free
text matches (see web appendix 1), and combined these to create
five non-overlapping usage groups: multivitamins, iron, iron
and folic acid, folic acid, or none (no use of multivitamins, iron,
or folic acid). For all analyses, this last group served as the
reference category against which we compared other supplement
use groups. The multivitamins category included those women
who noted use of any multivitamin, regardless of any combined
use with additional iron or folic acid, or both. Multivitamin
formulations in Sweden commonly include multiminerals; we
included these combinations in the multivitamins category.
Multiminerals such as calcium or magnesium supplements
without evidence of inclusion of iron or folic acid in the
formulation were classified as none. Since medical birth register
data do not reliably discern between multivitamins and antenatal
vitamins, they were combined and are referred to as
multivitamins. Register data also do not contain information
about dosage, timing of initiation, frequency, or duration.
Midwife interview of self reported maternal folic acid use has
been reported to correspond well with plasma folate levels
among Swedish women,25 so it is not unreasonable that other
supplements may also correspond well.
Covariates
National identification numbers enabled record linkage between
national registers held by Statistics Sweden and the National
Board of Health and Welfare. Registers utilised include the
medical birth register for child and pregnancy characteristics,20 26
the integrated database for labour market research for
socioeconomic factors,15 and national and regional health
registers for inpatient, outpatient, prescription drug, and
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psychiatric data.19 All covariates were chosen based on published
relations with ASD27 or the use of supplements, or both.
Child factors were sex, birth year (unordered single year
categories), and years of residence in Stockholm County
(continuous) to account for length of follow-up.
Sociodemographic data included maternal country of birth
(Sweden, other European, non-European), maternal education28
(pre-secondary, secondary, post-secondary, missing), and
disposable family income (fifths). Family income was calculated
after tax deductions, adjusted for family size, and based on birth
year to account for inflation. Maternal covariates included age
(<25, 25-29, 30-34, ≥35 years), parity (1, 2, ≥3), smoking at
first antenatal visit (yes, no, missing), body mass index (BMI)
at first antenatal visit (underweight: <18.5, normal: 18.5-24.9,
overweight: 25-29.9, obese: ≥30 kg/m2, missing). Web appendix
1 describes how we managed missing education, smoking, and
BMI data.
Lifetime history of maternal neurologic or psychiatric conditions
before the child’s birth (anxiety disorders, ASD, bipolar disorder,
depression, intellectual disability, non-affective psychoses,
stress related disorders, and epilepsy: yes or no for each (see
supplemental eTable 3)) were ascertained from the national
patient register and the Stockholm County adult outpatient
psychiatric register. Both registers have high validity.29
Medication use (antiepileptics and antidepressants: yes or no
for each) was ascertained using the medical birth register (self
reported at first antenatal visit by interview, available for the
entire study period) and the prescription drug register (records
of prescribed dispensed drugs, available for births from 2006
to 2007). Some validation work has been conducted examining
the concordance of maternal drug use during pregnancy in the
prescription drug register and the medical birth register. For
example, 69% of mothers with antiepileptic use recorded in the
prescription drug register also had corresponding information
in the medical birth register.30
Primary analyses
Odds ratios with 95% confidence intervals between supplement
intake and each outcome (ASD with intellectual disability, ASD
without intellectual disability, and any ASD) were calculated
using SAS software, version 9.3 (SAS Institute, Cary, NC) and
R.
We carried out sibling matched analyses using conditional
logistic models stratified by mother and adjusted for sex, parity,
and birth year.
Propensity score analyses were conducted separately for each
category of supplement use. Propensity scores were estimated
using logistic regression including all covariates with observed
or hypothesised associations with supplementation or ASD or
both. Odds ratios were calculated for matched samples using
generalised estimating equation models with logit link, clustered
by mother. Details of propensity score matching are described
in web appendix 1.
Multivariable regression analyses used generalised estimating
equation models with logit link, clustered by mother. Base
models were adjusted for child sex and birth year. Fully adjusted
models included all covariates mentioned.
Sensitivity analyses
Multivitamin categorization
As the multivitamin group contains all mothers that have taken
any multivitamins, we performed a post hoc sensitivity analysis
including mothers who used multivitamins without additional
iron or folic acid to isolate the association between ASD with
intellectual disability and multivitamins on their own as opposed
to a combination. Since primary analyses were conducted using
mutually exclusive exposure groups, we also analysed an
alternate approach using indicator variables for supplement use
to evaluate the specific associations of each supplement while
adjusting for the other supplements.
Maternal hospital stays
We hypothesised that underlying, possibly unobserved, health
factors might influence an apparent increase in risk associated
with use of only folic acid. To investigate, we carried out a post
hoc sensitivity analysis, stratifying by number of maternal
hospital stays during pregnancy excluding the delivery (0 v ≥1,
in approximately a 45 to 55 split). Although we considered other
health factors as stratification factors (eg, maternal epilepsy),
these analyses were not possible owing to the small number of
women who used folic acid and had children with ASD with
(n=15) or without (n=63) intellectual disability.
Unobserved confounding
We conducted a sensitivity analysis to determine how robust
observed associations of multivitamin use with ASD with
intellectual disability were to the presence of a hypothetical,
unobserved confounder (see web appendix 1).31
Patient involvement
No patients were involved in setting the research question or
the outcome measures, nor were they involved in developing
plans for design or implementation of the study. No patients
were asked to advise on interpretation or writing up of results.
There are no plans to disseminate the results of the research to
study participants or the relevant patient community.
Results
Study sample
The study sample consisted of 273 107 mother-child pairs,
categorized into groups: multivitamins (n=62 840, 23.0%), iron
only (n=90 138, 33.0%), iron and folic acid (n=25 445, 9.3%),
folic acid only (n=2789, 1.0%), and none of the above (n=91
895, 33.7%) (table 1⇓). The multivitamin group included
multivitamin only (n=17 539, 6.4%), multivitamin and iron
(n=37 046, 13.6%), multivitamin and folic acid (n=1602, 0.6%),
and multivitamin, iron, and folic acid (n=6653, 2.4%).
For the groups, event rates (ASD, ASD with intellectual
disability, ASD without intellectual disability) were,
respectively: multivitamins (1.7%, 0.3%, 1.4%), iron only (2.1%,
0.5%, 1.6%), iron and folic acid (2.0%, 0.5%, 1.5%), folic acid
only (2.8%, 0.5%, 2.3%), and none of the supplements (2.2%,
0.5%, 1.8%).
In the cohort, supplement user groups differed from one another
across multiple health and socioeconomic characteristics (table
1⇓). Compared with non-users, multivitamin users tended to be
older, primiparous, and more educated, have higher family
incomes, and were less likely to smoke and more likely to be
born in Sweden. Folic acid users were similar to multivitamin
users but were more likely than multivitamin users to be
immigrants, to be smokers, and have epilepsy or be taking
antiepileptics. Conversely, mothers taking iron only, or in
combination with folic acid, tended to be younger, multiparous,
and less educated, and to have lower family incomes, and were
more likely to be immigrants and smokers than non-users.
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Depression and antidepressant use were slightly more prevalent
among all categories of supplement users versus non-users.
Primary analyses
Multivitamin
Regression analysis indicated that multivitamin use was
associated with a lower likelihood of ASD with intellectual
disability compared with non-use of multivitamins, iron, and
folic acid in all analyses (odds ratio 0.69, 95% confidence
interval 0.57 to 0.84). Point estimates from the sibling control
(0.77, 0.52 to 1.15) and propensity score analyses (0.68, 0.54
to 0.86) were similar, although the sibling control estimate had
a wider confidence interval that included 1.0 and was therefore
not statistically significant (table 2⇓). Multivitamin use was not
associated with ASD without intellectual disability in any
analysis.
Iron and folic acid
Although imprecision owing to small numbers of folic acid only
users was evident, there was a suggestion of an increased
association between folic acid use and ASD without intellectual
disability in the multivariable regression (odds ratio 1.29, 95%
confidence interval 0.99 to 1.67) and sibling control (1.70, 0.94
to 3.10) analyses, that was attenuated in the propensity score
analysis (1.10, 0.83 to 1.48). Iron use was not associated with
ASD with or without intellectual disability in any analysis.
Sensitivity analyses
Multivitamin categorization
We tested whether the association between multivitamin use
and ASD with intellectual disability was sensitive to alternate
categorization and analytic approaches. Analysis of women who
used multivitamins without additional iron or folic acid yielded
an odds ratio estimate of 0.60 (95% confidence interval 0.44 to
0.84); also see eTable 4 in web appendix 1). In analyses using
indicator variables for supplement use and adjusted for the other
supplements, estimates for multivitamins and ASD with
intellectual disability in the regression (odds ratio 0.71, 95%
confidence interval 0.59 to 0.84) and sibling analyses (0.80,
0.55 to 1.17) were similar to estimates from primary analyses
(see eTable 5 in web appendix 1).
Maternal hospital stays
Evidence of an increased risk of child ASD with folic acid use
was limited to mothers with at least one hospital stay during
pregnancy (odds ratio 1.59, 95% confidence interval 1.21 to
2.10 for any ASD; see eTable 6 in web appendix 1). No evidence
of an increased risk with folic acid use was seen in mothers with
no hospital stays (0.84, 0.54 to 1.30 for any ASD). Importantly,
the associations of multivitamin use with lower risk of ASD
with intellectual disability persisted in this sensitivity analysis
(no hospital stays: 0.64, 0.47 to 0.87; any hospital stays: 0.75,
0.58 to 0.97).
Unobserved confounding
We found evidence to suggest that the association between
multivitamin use and ASD with intellectual disability was not
likely to be wholly a result of unobserved confounding. For
example, if a hypothetical binary confounder reduced the risk
of ASD with intellectual disability by 50% and was twice as
prevalent in multivitamin users (40%) versus non-users (20%),
the propensity score odds ratio estimate of 0.69 (95% confidence
interval 0.57 to 0.84) would attenuate to 0.78 (0.64 to 0.95).
Discussion
The present population based study used sibling controls,
propensity score matching, and multivariable regression to
examine associations of maternal nutritional supplementation
during pregnancy and risk of autism spectrum disorder (ASD)
in offspring. We could not rule out the possibility that
multivitamin supplementation may be inversely associated with
ASD with intellectual disability. Evidence that either iron or
folic acid use were inversely associated with ASD was
inconsistent.
Strengths and weaknesses of this study
The main strength of this study is the relatively large population
based sample in which advanced analytic methods were used
to gauge robustness of findings. In addition, the case finding
approach covered all pathways to ASD care and services in
Stockholm County, Sweden, in the context of a universal
healthcare system, thus increasing the likelihood that cases of
ASD were identified.
Sibling control32 and propensity score matching33 analyses were
used to examine whether results obtained using conventional
multivariable regression were likely to be influenced by either
observed or unobserved confounding. Such confounding is
likely, given that nutritional supplement users were different
from non-users in ways that may influence ASD risk. Propensity
score matching was effective in balancing covariate distributions
between exposed and unexposed children (see efig 1 in web
appendix 1). Multivariable regression and propensity score
findings were similar and suggest that observed confounding
is not responsible for observed associations, though unobserved
confounding remains a potential concern in these two analyses.
By comparing within sibling matched sets, sibling analyses
neutralize potential shared observed and unobserved confounders
that might predict both supplement use and ASD in childhood.
Sibling studies have lower sample sizes, which lead to imprecise
estimates and high type II error, as well as other limitations.34
In particular, sibling analyses have greater susceptibility to
potential non-shared confounders that change between
subsequent pregnancies (eg, nutritional depletion in the case of
short intervals between pregnancies) and random measurement
error of the exposure, which would be expected to attenuate
associations compared with conventional estimates.34 Since the
sibling estimate was not statistically significant at α=0.05, it
warrants cautious interpretation. In the present study, the sibling
analysis point estimate was similar to the multivariable
regression estimate, supporting the possibility that unobserved
confounding owing to shared characteristics was not driving
this association. Together, the three analyses appeared to point
toward a potential inverse association between multivitamin
use and ASD with intellectual disability.
The study has substantial limitations, such as the potential for
confounding. Our calculations of the potential impact of
unmeasured confounding suggest that to nullify the potential
association between multivitamin use and ASD with intellectual
disability an unmeasured confounder would have to be a strong
protective factor against ASD with intellectual disability,
exerting an effect above and beyond the covariates matched in
propensity score analyses (see eTable 7 in web appendix 1). An
editor suggested that a maternal trait that predicts multivitamin
use—higher intelligence—may decrease the risk of ASD with
intellectual disability. However, analyses controlled for maternal
education level, intellectual disability, and ASD. Moreover, the
sibling control analyses, which would be expected to control
for such a confounder, produced point estimates not inconsistent
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with the regression analysis. Behavioural confounding is also
another possibility, as healthy lifestyle is a well known
confounder in studies of nutritional supplement use.18 Our
analyses controlled for maternal body mass index but were
unable to assess the contribution of diet or other nutritional
supplements. Existing research on antenatal diet and ASD is
limited and further study is recommended.27 In addition, the
associations between multivitamin use and ASD with intellectual
disability could be related to ASD, intellectual disability, or
both. This could not be examined in the present study.
The observation that folic acid use was associated with higher
risk only in women admitted to hospital during pregnancy and
the absence of associations between the iron and folic acid group
and ASD suggests confounding by causes of hospital stays such
as chronic somatic or psychiatric conditions, acute illness,
pregnancy related disorders, or psychosocial distress.35-37
Whether this occurs through structural pathways (eg, folic acid
being prescribed at higher rates among women staying in
hospital during pregnancy) or through biological pathways (eg,
folate insufficiency as a result of a chronic condition or
medication) is unknown. Potential exposure to anti-folates
through either maternal history of epilepsy38 or use of an
antiepileptic medication39 during pregnancy have both been
associated with increased risk of ASD in children and were
more prevalent in the folic acid group, making confounding by
indication possible.
Another potential limitation was categorization of the
multivitamin group as having used multivitamins with or without
additional iron or folic acid, and the use of non-overlapping
supplement groups. However, sensitivity analyses examining
women who only used multivitamins without iron and folic acid
and analyses using indicator variables for supplement use instead
of supplement groups yielded similar estimates to those from
primary analyses.
Assessment of supplement use was limited, since type, timing,
and dose of supplements could not be determined. Changes to
nutritional status or supplement use after the first antenatal visit
could not be assessed. It is possible that the reported supplement
was not taken, or a supplement was taken but not reported.
While the extent of exposure misclassification is unknown,
prevalences of supplement use observed here are in the range
of estimates from other studies in the Swedish population during
the same period.40 41
Even if a causal association could be established between
multivitamin use and ASD with intellectual disability, it cannot
be determined from the data whether there is a critical window
for exposure, what specific nutrients or combinations thereof
may be responsible, or what dose is required. External validity
is also not assured, since different populations have different
backgrounds of supplement use, fortification, dietary patterns,
and health risks. Lastly, although the study featured a relatively
large sample size, small cell counts owing to rare outcomes
made it difficult to obtain precise estimates from lower powered
analyses, particularly the sibling control analyses.
Comparison with other studies
Our findings agree with some of the existing literature. The
three case-control studies reporting reduced risk of ASD with
antenatal vitamins,14 iron,13 and folic acid42 were from the
CHildhood Autism Risks from Genetics and Environment
(CHARGE) study in the USA.
Interestingly, lower mean folic acid intake in CHARGE was
found for children with ASD with a lower cognitive function
but not for ASD with higher functioning, suggesting that
nutrients may differentially affect ASD risk depending on
co-occurrence with intellectual disability. In the prospective
Norwegian Mother and Child Cohort study, maternal folic acid
intake, but not other vitamins and minerals, in the
periconceptional period and early pregnancy, was associated
with lower risk of ASD.11 The Danish National Birth Cohort
study reported null associations between folic acid and
multivitamin intake and ASD or any of its subtypes.12 To date,
all published studies of maternal folate biomarkers and ASD or
autistic traits in children have found null relations.43 44 However,
these biomarker studies also evaluated nutrient intake and
reported associations with reduced ASD symptoms.
Timing of exposure could have played a role in differences
among findings for iron and folic acid. In the current study,
supplementation was assessed at a median of 10.7 weeks’
pregnancy (interquartile range 9.0-12.7 weeks). The observed
association for folic acid intake in CHARGE was for use through
the first month of pregnancy, and findings were null after the
second month of pregnancy. For the Norwegian Mother and
Child Cohort study, the protective association pertained to use
through the first trimester, whereas the Danish National Birth
Cohort study examined use through eight weeks’ gestation.
Conversely, biomarker studies with positive findings had
assessed maternal folate after the first trimester.
Another possibility that may contribute to differences between
studies is that the background nutritional contexts of the
countries in which the studies are conducted differ. For example,
while the USA implements folic acid fortification, Sweden,
Norway, and Denmark do not. Fish oil supplements are routinely
taken in Norway by nearly 60% of pregnant women45 but are
rarely used in Sweden. Similarly, serum 25-hydroxyvitamin D
levels in pregnant women are lower in Sweden46 than in
Denmark,47 corresponding with the difference in latitude.
Such differences may help to explain why a reduced risk of
ASD with iron or folic acid use was not observed. Data suggest
that nutritional intake may differ between cohorts.48 Participants
in the Norwegian Mother and Child Cohort study reported
combined daily dietary and supplementary iron (40.4 mg) and
folic acid (615 μg)45 concentrations similar to levels associated
with protection against ASD in the CHARGE study (57.1 mg
iron13 and 600 μg folic acid42). Participants in the Danish
National Birth Cohort study reported 575 μg combined dietary
and supplementary folic acid.49 In contrast, combined dietary
and supplementary iron (15.0 mg) and folic acid (430 μg) intake
among Swedish pregnant women48 were less than in the
CHARGE study or the Norwegian Mother and Child Cohort
study. Taken together, it is not unreasonable to conclude that
effects of supplements taken in one country may differ from
those in another country, depending on whether combined
dietary and supplementary levels of nutrients reach a threshold
necessary to elicit protection.
Conclusions and policy implications
We observed a potential inverse association between maternal
multivitamin supplement use and ASD with intellectual
disability in offspring. Whether the association is specific to
autism or reflects the risk of intellectual disability needs to be
explored in future research. Given the current understanding
and strength of evidence supporting the importance of nutritional
supplementation during pregnancy, these results on their own
should not change current practice. Still, these findings raise
questions that warrant investigation. A sufficient body of
mechanistic evidence supporting the finding does not yet exist.
Verification in independent epidemiologic investigations with
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improved exposure assessment, perhaps in randomised studies,
is necessary before recommending a change to current practice.
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What is already known on this topic
Evidence from observational studies is inconsistent about whether maternal supplementation with multivitamins, iron, or folic acid is
protective against autism spectrum disorder (ASD) in offspring
Although the cause of autism spectrum disorder may differ by presence of intellectual disability, few studies have examined relations
between nutritional supplements and ASD based on level of cognitive function
What this study adds
This population based study of a large cohort in Stockholm supported a possible inverse association between maternal use of multivitamin
supplements in early pregnancy and ASD with intellectual disability in offspring compared with no maternal use of multivitamins, iron,
or folic acid
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Tables
Table 1| Selected characteristics of Stockholm youth cohort study sample born between 1996 and 2007 by maternal supplement use. Values
are numbers (percentages) unless stated otherwise
SupplementCharacteristics
None (n=91 895)Folic acid only (n=2789)Iron and folic acid (n=25
445)
Iron only (n=90 138)Multivitamins (n=62 840)
2045 (2.2)78 (2.8)516 (2.0)1872 (2.1)1064 (1.7)ASD
ASD with intellectual disability:
430 (0.5)15 (0.5)138 (0.5)422 (0.5)158 (0.3)  Yes
1615 (1.8)63 (2.3)378 (1.5)1450 (1.6)906 (1.4)  No
47 683 (51.9)1451 (52.0)12 855 (50.5)45 933 (51.0)31 990 (50.9)Boys
Parity:
41 679 (45.4)1335 (47.9)10 628 (41.8)38 780 (43.0)32 488 (51.7)  1
33 509 (36.5)995 (35.7)9161 (36.0)33 258 (36.9)21 927 (34.9)  2
16 707 (18.2)459 (16.5)5656 (22.2)18 100 (20.1)8425 (13.4)  ≥3
Maternal education:
43 019 (46.8)1365 (48.9)10 281 (40.4)36 613 (40.6)34 633 (55.1)  ≥12 years
499 (0.5)17 (0.6)258 (1.0)611 (0.7)242 (0.4)  Missing data
70 698 (76.9)2164 (77.6)16 399 (64.5)62 296 (69.1)51 571 (82.1)Maternal country of origin, Sweden
33 122 (36.0)1078 (38.7)6978 (27.4)25 012 (27.8)27 051 (43.1)Highest fifth of family income
30.9 (5.0)31.4 (5.0)30.5 (5.3)30.2 (5.2)31.3 (4.7)Mean (SD) maternal age (years)
Maternal smoking:
6523 (7.1)200 (7.2)2080 (8.2)8229 (9.1)3434 (5.5)  Yes
55 576 (60.5)2502 (89.7)22 393 (88.0)78 636 (87.2)57 080 (90.8)  No
29 796 (32.4)87 (3.1)972 (3.8)3273 (3.6)2326 (3.7)  Missing data
Maternal body mass index (kg/m2):
1503 (1.6)49 (1.8)729 (2.9)2435 (2.7)1715 (2.7)  Underweight (<18.5)
36 995 (40.3)1655 (59.3)14 960 (58.8)53 299 (59.1)40 593 (64.6)  Normal (18.5-24.9)
12 675 (13.8)526 (18.9)5065 (19.9)17 637 (19.6)10 287 (16.4)  Overweight (25-29.9)
4991 (5.4)205 (7.4)1884 (7.4)6131 (6.8)3207 (5.1)  Obese (≥30)
35 731 (38.9)354 (12.7)2807 (11.0)10 636 (11.8)7038 (11.2)  Missing data
Maternal medication use:
916 (1.0)38 (1.4)367 (1.4)1368 (1.5)1017 (1.6)  Antidepressant
125 (0.1)65 (2.3)215 (0.8)119 (0.1)118 (0.2)  Antiepileptic
Maternal neuropsychiatric conditions:
1176 (1.3)35 (1.3)347 (1.4)1209 (1.3)870 (1.4)  Anxiety disorders
120 (0.1)5 (0.2)34 (0.1)127 (0.1)64 (0.1)  Autism
176 (0.2)9 (0.3)56 (0.2)159 (0.2)115 (0.2)  Bipolar disorder
2434 (2.7)82 (2.9)695 (2.7)2571 (2.9)2036 (3.2)  Depression
470 (0.5)69 (2.5)282 (1.1)391 (0.4)347 (0.6)  Epilepsy
67 (0.1)2 (0.1)20 (0.1)68 (0.1)19 (0.0)  Intellectual disability
281 (0.3)11 (0.4)83 (0.3)258 (0.3)140 (0.2)  Non-affective psychotic disorders
1648 (1.8)70 (2.5)475 (1.9)1668 (1.9)1210 (1.9)  Stress disorders
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Table 2| Unadjusted and adjusted odds ratios (95% confidence intervals) for supplement use and autism spectrum disorder (ASD) with
and without intellectual disability, and any ASD







0.69 (0.57 to 0.84)0.54 (0.45 to 0.65)0.68 (0.54 to 0.86)0.77 (0.52 to 1.15)0.60 (0.42 to 0.86)  Multivitamin
0.95 (0.83 to 1.11)0.99 (0.87 to 1.14)0.96 (0.82 to 1.13)0.90 (0.67 to 1.21)0.84 (0.64 to 1.10)  Iron
1.03 (0.84 to 1.26)1.14 (0.93 to 1.38)1.06 (0.86 to 1.30)0.99 (0.63 to 1.57)0.81 (0.54 to 1.22)  Iron and folic acid
1.20 (0.71 to 2.01)1.16 (0.69 to 1.94)1.14 (0.64 to 2.04)0.94 (0.29 to 3.04)0.81 (0.28 to 2.36)  Folic acid
ASD without
intellectual disability:
0.94 (0.85 to 1.03)0.82 (0.75 to 0.89)0.95 (0.85 to 1.06)1.00 (0.83 to 1.20)0.93 (0.79 to 1.10)  Multivitamin
0.96 (0.89 to 1.04)0.92 (0.85 to 0.98)0.95 (0.88 to 1.04)0.96 (0.81 to 1.12)0.93 (0.81 to 1.07)  Iron
0.89 (0.79 to 1.00)0.85 (0.76 to 0.95)0.84 (0.74 to 0.94)1.00 (0.78 to 1.29)0.91 (0.73 to 1.13)  Iron and folic acid
1.29 (0.99 to 1.67)1.30 (1.00 to 1.68)1.10 (0.83 to 1.48)1.70 (0.94 to 3.10)1.46 (0.87 to 2.45)  Folic acid
Any ASD:
0.89 (0.82 to 0.97)0.76 (0.71 to 0.82)0.86 (0.78 to 0.95)0.95 (0.81 to 1.13)0.86 (0.74 to 1.00)  Multivitamin
0.96 (0.90 to 1.03)0.93 (0.87 to 0.99)0.93 (0.87 to 1.01)0.95 (0.83 to 1.09)0.91 (0.80 to 1.03)  Iron
0.92 (0.83 to 1.02)0.91 (0.82 to 1.00)0.89 (0.81 to 0.99)1.01 (0.81 to 1.25)0.89 (0.73 to 1.07)  Iron and folic acid
1.27 (1.01 to 1.60)1.27 (1.01 to 1.60)1.17 (0.89 to 1.51)1.48 (0.87 to 2.51)1.30 (0.82 to 2.06)  Folic acid
CLR=conditional logistic regression; OLR=ordinary logistic regression; GEE=generalised estimating equation logistic regression.
Analytic sample sizes are documented in supplemental eTable 1, ranging from 15 575 mothers and 16 086 children (folic acid use and ASD with intellectual
disability propensity score analysis) to 178 083 mothers and 273 107 children (any ASD multivariable sample analyses). *Matched on birth mother. †Propensity
scores were calculated with covariates (see ¶ below) as predictors of supplement use in ordinary logistic regression models (maternal age was a continuous
covariate); in the matched sample, propensity scores were used as predictors of ASD in generalised estimating equation logistic regression models grouped by
birth mother. ‡Grouped by birth mother. §Adjusted for child characteristics (sex and birth year) and parity. ¶Adjusted for child characteristics (sex, birth year, and
years resided in Stockholm County), socioeconomic indicators (education, family income, and maternal birth country), maternal characteristics (age, body mass
index, parity, smoking status), medication use during pregnancy (antidepressants or antiepileptics), and maternal neuropsychiatric conditions (anxiety disorders,
autism, bipolar disorder, depression, epilepsy, intellectual disability, non-affective psychotic disorders, and stress disorders).
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Figure
Fig 1 Derivation of study samples. ASD=autism spectrum disorder
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